The outcomes of this study will benefit scientists and engineers who develop biologic product manufacturing processes by providing a better understanding of drug product. In this talk, herb lutz, global consultant, will discuss the formation of protein aggregates and their. Here, we explore the potential of predicting and reducing the aggregation propensity of monoclonal antibodies. Largescale manufacturing of pharmaceutical antibodies is a complex activity that requires considerable effort in both process and analytical development. Given the high cell densities achievable in both mammalian cell culture and microbial processes, primary recovery can be a. Low ph elution can induce mab aggregation in protein a chromatography 7, 8. Since the approval of the first therapeutic monoclonal antibody in 1986. Individual antibodies vary widely in their propensity to form aggregates 5. Biomanufacturing of monoclonal antibodies mab involves a number of unit operations, including cell culture in a bioreactor followed by chromatography and filtration. Strategies for the assessment of protein aggregates in pharmaceutical biotech product development. The term antibody production has both general and specific meanings.
Introduction to antibody production and purification thermo. Secretory leakage of igg1 aggregates from recombinant chinese. Analysis of monoclonal antibodies and their fragments by size. This 31 st article in the elements of biopharmaceutical production series focuses on evolution of the purification platform for manufacturing of mab therapeutics. The agilent advancebio sec column, used with the agilent 1260 biolc system, proved capable of. See how oncolumn aggregation is dependent on the type of resin used and how one particular highresolution cation exchange resin allows for the lowest proportion of aggregate formation. In the broad sense, it refers to the entire process of creating a usable specific antibody, including steps of immunogen preparation, immunization, hybridoma creation, collection, screening, isotyping, purification, and labeling for direct use in a particular method. Various economic analyses estimate that process development and clinical manufacturing costs can. Removing aggregates in monoclonal antibody purification. Dec 16, 2016 aggregates in monoclonal antibody manufacturing processes biotechnol bioeng 2011, 108 7, 1494508.
Aggregates in monoclonal antibody manufacturing processes biotechnol bioeng 2011, 108 7, 1494508. A systematic framework to optimize and control monoclonal. The stability of 11 purified monoclonal human igg1 and igg4 antibodies, including an igg1based bispecific crossmab, was compared in downscale mixing stress models. Monoclonal antibodies can have monovalent affinity. This study demonstrated the suitability of cationexchange laterallyfed membrane chromatography lfmc for rapid and highresolution separation of monoclonal antibody. Largescale production has revolutionized the market for monoclonal antibodies by boosting its production and becoming a more practical method of production. Current trends in monoclonal antibody development and. Are you considering how best to manage and remove aggregates across your template. Due to their broad application range, monoclonal antibodies mab are used worldwide in a variety. Simultaneous removal of leached proteina and aggregates from monoclonal antibody using hydrophobic interaction membrane chromatography. Monoclonal antibodies are expensive to develop and to manufacture.
Hic as a complementary, confirmatory tool to sec for the. Factors influencing biotherapeutic monoclonal antibody. Removing the aggregates of an acidic monoclonal antibody. Trends in upstream and downstream process development for. Lang2 1manufacturing science and technology, lonza biologics porrin. It has been more than a decade since the industry started establishing the process platform. Processing impact on monoclonal antibody drug products.
Trends in upstream and downstream process development. As a result, aggregation has to be monitored throughout process development and manufacturing of a mab product. During the manufacturing process, the protein is exposed to multiple stress. Evolution of the monoclonal antibody purification platform. Current trends in monoclonal antibody development and manufacturing will provide readers with an understanding of what is currently being done in the industry to develop, manufacture, and release. Removal of leached protein a, antibody dimers and aggregates da, host cell proteins hcp, viruses and. Aggregation kinetics for monoclonal antibody products. Purification is intended to remove impurities, such as protein aggregates, but some such operations may actually generate protein aggregation 1. Reliable, timely and costeffective monoclonal antibody production and purification programs. The structure of the monoclonal antibody should be justified with respect to its mechanism of action. Review aggregates in monoclonal antibody manufacturing processes mar. Aggregates in the final drug product are undesirable for two major reasons. After completing this chapter, students will be able to.
Aggregate content of cht xt eluate mab s significant reduction of the mab s aggregate was achieved unosphere supra eluate. Humanized monoclonal antibody produced by mammalian cell culture may contain significant amounts of antibody dimers and smaller amounts of higher order aggregates. Aggregates in mab therapeutics pose a risk to patients. Mab aggregates may form during protein expression, downstream processing, and storage, and may be caused. Aggregation and chemical modification of monoclonal. Today, antibody concentrations of 35 gl are achieved routinely and some companies have attained up to 10 gl in fedbatch processes 5,6,8. Predicting aggregation propensity and monitoring aggregates. Review aggregates in monoclonal antibody manufacturing processes mara va. Antibodydrug conjugates adcs are monoclonal antibodies coupled to cytotoxic agents with stable linkers. Monoclonal antibody production a report of the committee on methods of producing monoclonal antibodies institute for laboratory animal research national research council national academy press washington, dc 1999. Adcs travel to target cells, where the antibody binds to its antigen expressed on. The agilent advancebio sec column, used with the agilent 1260 biolc system, proved capable of delivering high resolution analysis of mab aggregates with short run times. The principles described in this document apply to monoclonal antibodies used as reagents, as well as monoclonal antibody related products, such as fragments, conjugates, and fusion proteins. For example, we have seen issues in manufacturing, such as quality, process.
In custom antibody development, once target selection. In the creation of this study, we used the industry standard modelling software, biosolve process, to address these questions. Extremes of ph, ionic strength, temperature, concentration, shear forces, and other processing conditions can lead to increased aggregation. Prediction and reduction of the aggregation of monoclonal antibodies. Size exclusion chromatography analysis of antibody drug conjugates using the agilent 1260 infinity ii bioinert lc system. In the broad sense, it refers to the entire process of creating a usable specific antibody, including steps of. Aggregates have been characterized in mab purification and formulation. Monoclonal antibody mab products have emerged as an extremely important and valuable class of therapeutic products for the treatment of cancer and other diseases such as rheumatoid arthritis, autoinflammatory disease, allergic asthma, and multiple sclerosis 1, 2. This 31 st article in the elements of biopharmaceutical production series focuses. Watch our experts discuss which steps in the biomanufacturing process are involved in the formation or removal of aggregates and industryleading approaches. Preparative separation of monoclonal antibody aggregates by. Nonsizebased membrane chromatographic separation and.
Stress factors in mab drug substance production processes. Secretory leakage of igg1 aggregates from recombinant. Adcs travel to target cells, where the antibody binds to its antigen expressed on the cell surface. Pdf monoclonal antibodies have proved to be a highly successful class of therapeutic products. Monoclonal antibodies mabs are the fastestgrowing biological therapeutics with important applications ranging from cancers, autoimmunity diseases and metabolic disorders to emerging infectious diseases. Table 1 summarizes potential sources of aggregate formation during. The study focuses on very large scale processes in the region of five 5 tonnes per annum of bulk antibody. For some years, new methodologies have advanced with new production processes, allowing scaleup production and market introduction. Aggregates in monoclonal antibody manufacturing processes ifm.
To investigate antibody stability and formation of modified species under upstream processing conditions. Preparative separation of monoclonal antibody aggregates. Schematic manufacturing process of monoclonal antibodies from cell. The study of aggregation propensity of a monoclonal antibody mab and its. Thus, values obtained from sec may not actually represent the true aggregate levels in the protein drug container, so there is a continued effort to.
Aggregates in monoclonal antibody manufacturing processes. In this talk, herb lutz, global consultant, will discuss the formation of protein. Protein a chromatography increases monoclonal antibody aggregation rate during subsequent low ph virus inactivation hold. The control and avoidance of aggregation in the manufacturing process are needed because aggregates affect drug performance and safety97,98. Aggregation mechanism of an igg2 and two igg1 monoclonal antibodies at low ph. Quality attributes of monoclonal antibodies and effect of cell culture. Protein a chromatography pac is commonly used as an efficient capture step in monoclonal antibody mab separation processes. Selecting the optimal resins for aggregate removal references he x et al. Antibody aggregation could be triggered by partial unfolding of its domains, leading to monomermonomer. Guideline on development, production, characterisation and. For the final biopharmaceutical product approval and subsequent manufacturing processes, a comprehensive characterization of mab purity, aggregate forms, and charge variants is required by the regulatory agency. A read is counted each time someone views a publication summary such as the title, abstract, and list of authors, clicks on a figure, or views or downloads the fulltext.
This study demonstrated the suitability of cationexchange laterallyfed membrane chromatography lfmc for rapid and highresolution separation of monoclonal antibody mab aggregates. Integrated flowthrough purification for therapeutic. This hydrophobicity can be problematic during manufacturing and storage in terms of aggregate formation as well as in analytical characterization of the latter1. Pdf aggregates in monoclonal antibody manufacturing. Pdf aggregates in monoclonal antibody manufacturing processes. Monoclonal antibodies mabs are the fastestgrowing biological therapeutics with important applications ranging from cancers, autoimmunity diseases and metabolic disorders to. Understanding and managing aggregates are critical to your monoclonal antibody mab process. Clarification technologies well established in other industries, such as flocculation and precipitation are increasingly considered as a viable solution to address this bottleneck in antibody processes. Mar 25, 2018 aggregates in monoclonal antibody manufacturing processes. One of these molecules was further evaluated in realistic bioreactor stress models and in cell culture fermentations. Aggregation mechanism of an igg2 and two igg1 monoclonal. Monoclonal antibodies mabs are a successful class of therapeutic products used increasingly in the past 1520 years, but the manufacture of safe and effective mab drug products provides many challenges to downstream molecule purification. Removing the aggregates of an acidic monoclonal antibody with. Taken together, these developments are driving the industry to explore alternative separation technologies as a future manufacturing strategy.
Aggregates in monoclonal antibody manufacturing processes marava. These include production cell culture, harvest, antibody capture by protein a, virus. Upon binding, the full adc can be internalized by a process called receptormediated endocytosis. Overall purification performance of cht xt chromatography is summarized in table 1. Introduction to antibody production and purification. Analysis of monoclonal antibodies and their fragments by. Antibody aggregation can occur at various stages including the up and downstream processes in manufacturing, formulation, and longterm storage 5, 6. The primary objective of this project was to use the experimental analysis together with the knowledge of chemical kinetics to build a kinetic model for protein. The formation of aggregates is a common but highly undesirable occurrence during monoclonal antibody purification. Monoclonal antibodies mab or moab are antibodies that are made by identical immune cells that are all clones of a unique parent cell. Capto adhere is a multimodal ion exchanger and is designed to be used as a second or third step in monoclonal antibody mab puri. Current trends in monoclonal antibody development and manufacturing will provide readers with an understanding of what is currently being done in the industry to develop, manufacture, and. Usp manufacturing processes which generate higher titers still take. There is a clear need to reduce costs and manufacturing risk in order to.
Production processes for monoclonal antibodies intechopen. Size exclusion chromatography analysis of antibody drug. Dec 16, 2016 understanding and managing aggregates are critical to your monoclonal antibody mab process. Managing aggregates in your monoclonal antibody mab process. Aggregation of mabs continues to be a major problem in their developability. Jan 16, 20 to investigate antibody stability and formation of modified species under upstream processing conditions. Largescale manufacturing of pharmaceutical antibodies. For the final biopharmaceutical product approval and subsequent manufacturing processes, a comprehensive characterization of mab. Monoclonal antibody mab products have emerged as an extremely important and valuable class of therapeutic products for the treatment of cancer and other diseases such. The stability of 11 purified monoclonal human igg1 and igg4. Given the high cell densities achievable in both mammalian cell culture and microbial processes, primary recovery can be a significant challenge at lab, pilot and commercial manufacturing scales. Review aggregates in monoclonal antibody manufacturing processes marava. The current trend for cell culture processes is to increase. Impact of media and antifoam selection on monoclonal.
Howe ver, their applicability will be determined on a case bycase basis, based on their specific properties, and may be addressed in specific annexes. Recovery and purification process development for monoclonal. Monoclonal antibody production in commercial scale cell culture bioprocessing requires a thorough understanding of the engineering process and components used. To demonstrate the analysis of monoclonal antibody mab aggregates. But this method can provide misleading results because aggregates can dissociate or form during sec andor adsorb to the column resin. Monoclonal antibodies have proved to be a highly successful class of therapeutic products. Jan 09, 2018 the formation of aggregates is a common but highly undesirable occurrence during monoclonal antibody purification. Imbaratto, cell culture manufacturing, covance biotechnology services, inc. The small molecules attached to the mab are often relatively hydrophobic.
156 896 1038 614 817 1215 905 1468 1444 1206 575 457 1028 1447 290 917 519 402 1485 780 1449 861 579 1184 1471 31 1138 1392 1432 524 966 697 883 1483 937 1193 108 380 417